THE DONOWAY CENTER

Pancreatic NanoKnife Tumor Ablation for Advanced and Oligo-Metastatic Pancreatic Cancer

Dr. Donoway is using multi-modality therapy combining Pancreatic NanoKnife Tumor Ablation with chemoimmuno-radio therapy to treat advanced-stage cancer patients worldwide after they have stopped responding to the standard of care therapy and have been left with few options for further treatment.

groundbreaking treatment by Dr. Donoway, which is FDA-approved. Dr. Donoway also treats other advanced cancers, such as liver, Breast, and sarcomas, using NanoKnife Surgery based on its FDA-approved guidelines. Patients experience a brief recovery, which means the patient can start chemotherapy and radiation much sooner.

Dr.

With over 32 years of experience performing pancreatic surgery in south Florida, Dr. Donoway recognized that because of late diagnosis, up to 85% of patients treated for pancreatic cancer already had metastatic disease at the time of diagnosis. This fact limited the benefit many patients might receive from pancreatic surgery, which is problematic as surgery has long been held to be the only reproducible therapy for a cure. In reality, surgery is currently more likely Palliative in almost 80% of the cases.

Recent evidence shows that when even advanced disease is treated aggressively in an integrated approach, incorporating NanoKnife surgery with chemotherapy and now supplemented with immunotherapy, long-term survivorship can be achieved, especially when compared to chemotherapy alone.

Dr. Donoway has been a pioneer in using pancreatic NanoKnife, especially for complex cases. During the past decade, patients worldwide have traveled to benefit from this

Dr. Donoway feels that “we are long overdue to revise our approach to treating Pancreatic cancer. The treatment history has been largely unchanged for over 80 years and has just broken the 10% five-year survivorship barrier. Only thru thinking outside the box will we accomplish the positive. Otherwise, we’re all confirming Einstein‘s definition of insanity.”

Dr. Donoway is involved in ongoing research in identifying the best chemo-immuno therapy and sequencing to be used along with Pancreatic nanoKnife/ IRE. Dr. Donoway states, “the results so far have been very encouraging, and we have begun using it for other select cancers. Among his longest survivors are now patients over nine years without evidence of cancer recurrence. In the past, without IRE, they would have lived a little over a year, so this technique opens a new avenue for treating those eligible patients in a more targeted fashion.”

Dr. Donoway presented his results of pancreatic ablation at the recent annual meeting of the American Pancreatic Association. For more information about Dr. Donoway and the pancreatic IRE/NanoKnife program, call 954-986-6366 or visit www.atlasoncology.com.